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Abstract
Background: Although muscle weakness is a hallmark of facioscapulohumeral muscular dystrophy (FSHD), the
molecular mechanisms that lead to weakness in FSHD remain largely unknown. Recent studies suggest aberrant
expression of genes involved in skeletal muscle development and sarcomere contractility, and activation of
pathways involved in sarcomeric protein degradation. This study will investigate the contribution of sarcomeric
protein dysfunction to the pathogenesis of muscle weakness in FSHD.
Methods/Design: Evaluation of sarcomeric function using skinned single muscle fiber contractile studies and
protein analysis in muscle biopsies (quadriceps femoris and tibialis anterior) from patients with FSHD and age- and
gender-matched healthy controls. Patients with other forms of muscular dystrophy and inflammatory myopathy will
be included as disease controls to assess whether results are due to changes specific for FSHD, or a consequence
of muscle disease in general. A total of 56 participants will be included. Extensive clinical parameters will be
measured using MRI, quantitative muscle studies and physical activity assessments.
Discussion: This study is the first to extensively investigate muscle fiber physiology in FSHD following an earlier
pilot study suggesting sarcomeric dysfunction in FSHD. The results obtained in this study will increase the
understanding of the pathophysiology of muscle weakness in FSHD, and possibly identify novel targets for
therapeutic intervention.
Keywords: Facioscapulohumeral muscular dystrophy, Oculopharyngeal muscular dystrophy, Sporadic inclusion
body myositis, Skeletal muscle, Sarcomere, Myofilament
Background
Facioscapulohumeral muscular dystrophy (FSHD) is the
third most common hereditary myopathy, affecting
1:15,000-20,000 people [1]. Age of onset and disease se-
verity is variable, although in general presentation starts
in the second decade of life [2]. FSHD derives its name
from the characteristic early involvement of the muscles
of the face, shoulder girdle and upper arm, which, in
contrast to other muscular dystrophies, is often asym-
metrical. Further in the disease course weakness pro-
gresses to the foot dorsiflexors, abdominal and proximal
leg muscles [3]. About 20% of patients become wheel-
chair dependent [4].
FSHD1 (OMIM #158900), the most common type of
FSHD, is an autosomal dominant disorder caused by a
contraction of the D4Z4 repeat array, a macrosatellite re-
peat array consisting of 3.3 kb large D4Z4 units located on
chromosome 4q. FSHD patients have 1 – 10 repeat units,
in contrast to unaffected individuals who have 11 – 100
units [5,6]. Residual repeat length is roughly and inversely
correlated to disease severity and onset. Patients having
1 – 3 repeats usually show infantile onset and rapid dis-
ease progression [7]. The repeat array contraction leads
to a more open D4Z4 chromatin configuration, which
is hypothesized to permit transcription of otherwise epige-
netically silenced genes located on chromosome 4 [5,6].
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For FSHD to develop, there also needs to be a permissive
genetic background of chromosome 4, as described below.
In a minority of patients with a FSHD phenotype there is
no D4Z4 contraction. These patients are categorized as
FSHD2 and the majority of them have a mutation in the
chromatin modifier SMCHD1 [8,9]. Both FSHD1 and
FSHD2 share the above-mentioned changes in D4Z4
chromatin configuration in somatic tissue on a FSHD-
permissive chromosome 4 background.
FSHD candidate genes include Double Homeobox Pro-
tein 4 (DUX4) and FSHD Region Gene 1 (FRG1). Permis-
sive chromosome 4 backgrounds contain a polymorphic
DUX4 polyadenylation signal, which facilitates ectopic ex-
pression of DUX4 in skeletal muscle upon D4Z4 chroma-
tin opening. DUX4 is currently considered the primary
mediator of FSHD pathology, and activates the p53 and
caspase-3 pathways when overexpressed in mice. Both of
these pathways are involved in skeletal muscle differenti-
ation, sarcomeric protein degradation and apoptosis
[10,11]. DUX4 may also activate ubiquitin-mediated pro-
tein degradation pathways including E3 ubiquitin ligases
such as Atrogin-1 and MuRF1 [12,13]. These muscle spe-
cific ligase enzymes specifically target sarcomeric proteins
and have been implicated in the atrophic phenotype in
FSHD myotubes [13,14]. FRG1 is localized to the Z-disc
of the sarcomere and functions as an actin-binding and
bundling protein [15,16]. Overexpression of FRG1 in mice
causes muscular dystrophy and vascular abnormalities,
both features of FSHD [17,18]. Taken together, these find-
ings suggest that expression of FSHD candidate genes
such as DUX4 or FRG1 have downstream effects on sarco-
mere development and sarcomere turnover.
The sarcomere – the smallest contractile unit in muscle –
is composed of several proteins that work together to
enable muscle contraction. Upon activation with calcium,
cross-bridges are formed between actin and myosin fila-
ments. This induces filament sliding and enables muscle
contraction. Other important constituents of the sarco-
mere include titin, which stabilizes the sarcomere and
contributes to passive force, and nebulin, which plays an
important role in the regulation of actin filament length.
We hypothesize that dysfunction of sarcomeric pro-
teins contributes to the pathogenesis of muscle weakness
in FSHD. A pilot study in 4 FSHD muscle biopsies
performed in our laboratory supports this hypothesis
[19]. The present study aims to confirm these data in a
larger cohort and elucidate the causes of sarcomeric dys-
function in FSHD. Secondary objectives are:
– To determine whether sarcomeric dysfunction is
specific for FSHD, or part of a generalized pathology
common to muscular dystrophy and/or
inflammatory myopathy. To investigate this, patients
with oculopharyngeal muscular dystrophy (OPMD)
and sporadic inclusion body myositis (sIBM) will be
included in the study as disease controls.
– To explore other contractile properties of FSHD
muscle fibers such as cross-bridge cycling kinetics,
calcium sensitivity and passive force generation.
With this, we aim to clarify the cause of sarcomeric
dysfunction in FSHD.
– Compare sarcomeric function in muscles affected
early (tibialis anterior) and late (quadriceps femoris)
in the disease course of FSHD to shed light on the
remarkable distribution of weakness in FSHD. Also,
by assessing these muscles within the same patient
we will be able to determine when sarcomeric
dysfunction occurs in the pathological process.
– Correlate in vitro sarcomeric function to in vivo
clinical parameters such as physical activity, muscle
strength, disease severity, residual D4Z4 fragment
length, muscle/fat fraction and quantitative muscle
studies.
– This study will also provide extensive new data on
sarcomeric function in OPMD and sIBM. This will
result in a better understanding of these disorders and
generate new hypotheses for research and treatment.
Methods/Design
Study population
Genetically confirmed patients with FSHD1 will be
recruited from the Radboud university medical center.
Healthy individuals without a history of neuromuscular
disease will be included as healthy controls. Two disease
control groups (one with muscular dystrophy and one
with inflammatory myopathy) will be included to deter-
mine whether the results obtained in this study are spe-
cific for FSHD, or a general feature of muscular
dystrophy or inflammation – both histological features
of FSHD. For the muscular dystrophy disease control
group, patients with genetically confirmed OPMD (12–
17 trinucleotide repeats in PABPN1) will be included.
OPMD was chosen because it is a relatively common
muscular dystrophy, has an adult age of onset and has
no associated systemic features which might influence
muscle fiber function. Also, patients are not likely to be
wheelchair bound, which is an exclusion criterion for
this study. For the inflammatory myopathy control
group, patient with sIBM fulfilling the modified 2010
Griggs criteria will be included [20]. We have chosen
sIBM because it is relatively common, has clearly delin-
eated histological features and diagnostic criteria, and
patients are not treated with corticosteroids, which is an
exclusion criterion for this study. The full list of exclu-
sion criteria is as follows:
– Age <18 or >65 years
– Diabetes mellitus
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– Chronic obstructive pulmonary disease
– Chronic heart failure
– Current malignancy
– Previous treatment with chemotherapy and/or
radiation therapy
– Use of corticosteroids during more than two weeks
in the past 5 years
– Use of statins in the past year
– Wheelchair bound
– Contra-indications for MRI or muscle biopsy
– Pregnancy
In each group, 14 participants will be included for a
total of 56 participants. Age and gender matching will
be applied on the group level. The Medical Ethics
Review Committee region Arnhem-Nijmegen approved
the study protocol.
In vivo study procedures
General
Information on medical history and current medication
use will be collected. Body weight and length will be
measured. Parameters of muscle injury will be assessed
in serum (creatine kinase (CK), lactic dehydrogenase
(LDH), aspartate transaminase (AST) and alanine
transaminase (ALT)). In FSHD patients, disease severity
will be assessed using the Ricci Clinical Severity Scale
(CCS) and the CSS corrected for age: age-corrected
CSS (ACCSS) [21-23].
Physical activity and muscle strength
Physical activity will be assessed in several ways. Partici-
pants will be equipped with an actometer, a device that
is attached to the ankle to constantly measure physical
activity during 12 days [24,25]. Validated questionnaires
will be administered to assess participants' daily living ac-
tivities, disease impact and possible confounding factors
such as pain: Health Assessment Questionnaire (HAQ)
[26], International Physical Activity Questionnaire (IPAQ)
[27], Sickness Impact Profile (SIP 68) [28], McGill’s Pain
Questionnaire (MPQ) [29]. Muscle strength will be graded
with the Medical Research Council (MRC) scale [30]. A
trained examiner will obtain a Motor Function Measure
[31]. In addition, a six-minute walk test and timed up and
go test will be performed [32,33].
Quantitative muscle studies
Isometric force recordings of maximal voluntary and
electrical evoked contractions of the quadriceps femoris
will be performed as described previously [34]. Partici-
pants will be seated in a custom-build chair with the
knee angle set at 120°. To prevent compensatory move-
ments, participants are strapped at the hips and upper
body to maintain their position. Electrical pulses will be
delivered through two self-adhesive surface electrodes
placed proximally over the rectus femoris and distally
over the vastus medialis portion of the quadriceps
muscle. Two gel electrodes will be used to make a sur-
face electromyogram (sEMG).
Maximum voluntary contraction All measurements
will be performed in the leg from which the muscle
biopsy will be taken (i.e., the right leg, unless in the pres-
ence of asymmetrical weakness in which case the
weakest leg will be biopsied). Participants will be asked
to perform a Maximum Voluntary Contraction (MVC)
during 3 seconds. The highest force from three contrac-
tions is used to represent the MVC. Next, the 100 Hz
current that evokes 30% of MVC will be determined and
used for all subsequent measurements.
Contractile properties After a 5-minute rest period, the
force–frequency relation will be determined with 1 Hz,
100 Hz, 1 Hz, 10 Hz, 20 Hz, 30 Hz, and 50 Hz pulse trains
of 1 s duration. There will be a 1-minute rest period after
each contraction. The 1 Hz stimulation will be performed
multiple times to verify that the 100 Hz pulse train causes
no fatigue or potentiation. The contraction time, rate of
force rise, and early and late relaxation times will be de-
rived from the 100 Hz contraction (positively filtered with
a 30 Hz filter frequency). These parameters provide a
measure for the rate of cross-bridge cycling and the rates
of Ca2 reuptake by the sarcoplasmic reticulum.
Fatigue After another 5-minute rest period, a series of
30 Hz 1 s on 1 s off pulses will be applied for a period of
2 minutes to determine muscle fatigability. Fatigue is de-
termined as the relative decline of force between the first
three contractions compared with that of the last three
contractions.
MRI
A MR exam of the upper and lower leg will be performed
in all participants using a 3 Tesla MR system (Tim TRIO,
Siemens, Erlangen, Germany) with the spine array coil
and two phased-array coils placed around the legs. A fish-
oil marker will be placed on the site where the muscle bi-
opsy will be taken from, to ensure that MRI findings cor-
respond to the approximate site of muscle biopsy. Patients
will be placed in the scanner feet first supine. The table
will be positioned to have first the upper and subsequently
the lower leg in the isocenter of the magnetic field for im-
aging of the thigh and calf muscles respectively.
Scout images will be acquired in three orthogonal direc-
tions for accurate positioning of the MRI slices. Thereafter
8 transversal slices (FOV 175×175 mm2, thickness 4 mm,
gap 6 mm, baseresolution 256) will be acquired with a T2
multi spin echo sequence (TR: 3000 ms, 16 equally spaced
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echo times 7.7 – 123.2 ms). Subsequently followed by 23
transversal slices (thickness 4 mm, gap 0.4 mm) that will
be obtained with a T1 turbo spin echo sequence (FOV
250×244.5 mm2, TR/TE 600 ms/13 ms, baseresolution
448), and with a Turbo Inversion Recovery sequence
(TIRM) (FOV 175x175 mm2, TR/TE/TI 4100 ms/41 ms/
220 ms, baseresolution 256). The same imaging protocol
will be used for both the upper and lower leg.
Hyperintensities on the TIRM images will be detected
visually as an indicator for edema and/or inflammation
[35]. Muscle fraction at the slice corresponding to the
approximate site of muscle biopsy will be quantified
using the method described by Kan [36].
In vitro study procedures
Muscle biopsies
One needle muscle biopsy of the quadriceps femoris
(vastus lateralis), and one of the tibialis anterior will be
obtained from each participant. The tibialis anterior is fre-
quently affected in FSHD, but early involvement of the
quadriceps femoris is uncommon [3,37]. In the presence
of symmetrical muscle strength, the right side will be bi-
opsied. In case of asymmetrical weakness based on neuro-
logical examination, the weakest muscle will be biopsied.
An experienced neurologist or neurology resident, tak-
ing routine antiseptic precautions, will perform the muscle
biopsies. Biopsy material intended for histology will be
frozen in isopentane and stored at −80°C. Material for
protein analysis will be immediately frozen in liquid nitro-
gen and stored at −80°C. Specimens intended for contract-
ile studies are stored at −20°C in a glycerinating solution
containing half glycerol and half relaxing solution. For
composition of this solution, see below.
Muscle fiber preparation
For contractile studies, biopsy material will be placed
in a relaxing solution containing 1% (v/v) Triton X-100
at 4°C [38]. Triton is used to permeabilize the plasma
membranes, resulting in “skinned” muscle fibers. The
skinning process enables studies of sarcomeric function
in isolation by eliminating the confounding effects of
upstream processes of excitation-contraction coupling,
such as sarcoplasmatic reticulum Ca2+ handling. Prote-
ase inhibitors will be added to the solution to prevent
protein degradation. Skinned single muscle fibers will
be isolated and fiber ends will be attached to aluminum
t-clips. The clips are then mounted to a length motor
on one end, and a force transducer on the other.
Muscle fiber mechanics
Maximum force generation and cross-bridge cycling
kinetics Skinned muscle fibers will be activated by se-
quentially bathing them in a relaxing solution, pre-
activation solution and activation solution. The com-
position of these solutions has been described previ-
ously [39]. Force generating capacity will be measured
at a sarcomere length of 2.5 μm. Maximal force generating
capacity will be measured at pCa 4.5 and corrected for
cross-sectional area. To determine whether changes in
maximal force are due to changes in the kinetics of cross-
bridge attachment and detachment, a rapid stretch-release
protocol will be imposed on an activated fiber. The rate
constant of tension redevelopment (Ktr) will be deter-
mined by fitting the rise of tension to the following equa-
tion: F = Fss(1 – e
-Ktr·t) [40]. After force redevelopment
reaches the steady-state maximal force again, active stiff-
ness will be determined. Length changes of sequentially
0.3, 0.6, 0.9, -0.3, -0.6 and −0.9% will be applied, during
which peak force is measured. Corrected peak force will
be linearly plotted against the imposed length changes,
with the slope representing the fraction of strongly at-
tached cross bridges [41].
Calcium sensitivity of force generation During daily-
life muscle activation, individual fibers typically function
at a submaximal level. Therefore, the calcium sensitivity
of force generation provides additional information on
contractile properties. The calcium sensitivity of force
generation will be measured by bathing skinned muscle
fibers in activation solutions with different pCas ranging
from 4.5-7.0 and measuring steady-state force. The
obtained force-pCa data will be fitted to the Hill equa-
tion, providing the pCa50 (the pCa giving 50% of max-
imal active tension) and the Hill coefficient, nH (an
index of myofilament cooperativity) [42].
Passive force generation Passive force generation will
be measured by placing skinned muscle fibers in a cham-
ber filled with relaxing solution and imposing length
changes as previously described [43]. The fibers will be set
to their slack length (i.e. the length at which passive force
is zero) and from there they will be stretched with a con-
stant velocity to a sarcomere length of 3.2 μm, held for
90 s and then released back to slack length. Tension devel-
opment during stretch will be determined.
Muscle protein analysis
To study whether changes in sarcomere contractile func-
tion are a consequence of proteomic alterations, extensive
protein analysis using SDS-PAGE and Western blotting
will be performed as described previously [43,44]. We will
pay special attention to myosin heavy chains, actin,
titin, nebulin and regulatory proteins such as troponin
and tropomyosin. In addition we will determine oxidation/
nitrosylation (i.e. posttranslational modifications in re-
sponse to oxidative stress) of sarcomeric proteins by
Oxyblot and Western blotting, as described previously [45].
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To study whether decreased maximal force generation
is a result of decreased contractile protein content, we
will determine myosin content per half sarcomere and
will relate the results to the force generated by those
fibers as described previously [46]. In brief, myosin
heavy chain (MHC) content and MHC isoform compos-
ition will be determined using SDS-PAGE. We will cal-
culate fiber myosin concentration by dividing total MHC
content by fiber volume (at a sarcomere length of
2.5 μm). This fiber myosin concentration will be multi-
plied by half-sarcomere volume to calculate MHC con-
tent per half sarcomere. Finally, MHC content per half
sarcomere will be related to muscle fiber mechanics.
For analysis of titin and nebulin exon composition, we
will use a titin/nebulin exon microarray that consists of
50-mer oligonucleotides representing all exons in the
titin gene, spotted in triplicate on the array. The array
contains human titin and nebulin genes as well as all
known titin-binding proteins [47].
Histology
Histology will be used for light-microscopic evaluation
of frozen sections. We will study size, shape, type and
cytoarchitecture of muscle fibers, presence of internal-
ized nuclei, destruction of muscle fibers and regener-
ation, as well as supporting connective tissue.
Outcome assessment
The primary outcome measurement of this study is the
maximum force generating capacity (mN/mm2) of perme-
abilized single muscle fibers of FSHD patients and healthy
control subjects. Secondary outcome measurements are:
– The maximum force generating capacity of OPMD
and sIBM fibers in relation to FSHD fibers.
– Contractile properties of FSHD fibers such as cross-
bridge cycling kinetics, calcium sensitivity and passive
force generation in relation to fibers of healthy controls.
– Maximum force generating capacity and contractile
properties of muscle affected early (tibialis anterior)
compared to muscle affected late (quadriceps
femoris) in the disease course.
– Analysis of sarcomeric proteins and titin and
nebulin exon composition of FSHD muscle.
– In vivo clinical parameters such as physical activity,
muscle strength, disease severity, residual D4Z4
fragment length, muscle/fat fraction and quantitative
muscle studies.
Statistical analysis and power calculation
Statistical analysis
Differences between the above-mentioned outcome mea-
surements will be analyzed using analysis of covariance
(ANCOVA). A p value <0.05 will be considered significant.
Power
Due to the exploratory nature of this study, there are
virtually no previous studies to refer to for power calcu-
lations. Based on our pilot study, we aim to test the hy-
pothesis that there is a difference in maximum force
generating capacity of 7 mN/mm2 (~10% of FSHD
maximum force generation), with standard deviations
of 6 mN/mm2, α = 0.05 and β = 0.20. This hypothesis
requires a sample size of 13 subjects per group. Because
the muscle tissue can be damaged during the biopsy
procedure, we anticipate that ~10% of the collected bi-
opsies will not be useful for experiments. This brings
the total sample size to 14 subjects per group.
Discussion
Over the past decades, the identification and under-
standing of the complex genetic and epigenetic mechan-
ism underlying FSHD has been the primary focus of the
scientific community. Recently, this effort resulted in a
unifying genetic model for FSHD [5]. However, many
questions concerning the molecular and physiological
mechanisms underlying muscle weakness in FSHD re-
main unanswered. This study aims to look at the patho-
physiology of FSHD from a different perspective, and is
the first to extensively investigate the pathophysiology of
muscle weakness in FSHD.
A major strength of this study is the combined analysis
of extensive in vitro and in vivo data in the same cohort
of patients and control subjects. This will provide the
unique opportunity to increase our understanding of the
relationship between pathophysiological mechanisms
and the clinical condition of the patient. Biopsies of two
muscles with either early or late involvement (tibialis an-
terior and quadriceps femoris, respectively) will be col-
lected specifically for this study to provide insight into
the consequences of disease progression and the distri-
bution of weakness in FSHD. Studies of patients with
other forms of muscular dystrophy and inflammatory
myopathy will not only indicate whether the observed
changes found are specific to FSHD or a consequence of
neuromuscular disease in general, but will also provide
unique insights into the pathophysiology of these
disorders.
The study of muscle biopsies from FSHD patients
means that the data acquired will reflect consequences
of pathology in adult, differentiated human muscle cells.
This prevents possible confounders that may arise with
other frequently used methods in FSHD research such
as myotubes, myoblasts or mouse models.
As in all studies that use biopsies, the sampled mater-
ial represents only a small part of the muscle. This is a
risk especially in FSHD, which is characterized by a
marked difference in muscle pathology even within the
same muscle. In this study, we will use MRI imaging of
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the area of muscle biopsy to provide information on at-
rophy, muscle/fat fraction and inflammation to correct
for sampling error.
In conclusion, this study will provide new insights in
sarcomeric function of patients suffering from FSHD,
and correlate these to clinical measures in the same pa-
tients. This will be an important step in the understand-
ing of the pathophysiology of muscle weakness in this
disease, possibly identifying novel targets for therapeutic
intervention.
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